
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings is a radiopharmaceutical-focused company that produces and markets products used to Find, Fight and Follow cancer and diseases. The company has a strong portfolio of products that address unmet needs within the cardiology and oncology arenas, with leading products including PYLARIFY and DEFINITY. Despite potential competition and pressure on maintaining and expanding their commercial footprint, Lantheus is well-positioned for continued growth and success with its ongoing FDA approvals, anticipated pipeline growth, and strong financials. Additionally, the company has a strategic plan in place to secure reimbursement and maintain regulatory compliance, mitigating potential risks in those areas.
Bears say
Lantheus Holdings is performing well in the short term with strong revenue and margin beats in Q1. However, the focus on 2027 and lack of expected contributions from new opportunities dampen their long-term growth potential. While the royalty opportunities provide some upside, the stock is still undervalued and has room for growth, but not enough to justify a higher valuation in the near future.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares